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ABSTRACT
Objective and hypothesis: To evaluate the effectiveness of three commercial ELISA rapid tests
in comparison with qPCR for the diagnosis of canine parvovirus infection using fecal sample. It
was hypothesized that the ELISA rapid tests evaluated in this study are as effective as qPCR
method in diagnosis of canine parvovirus infection in fecal samples.
Background: Canine parvovirus-2 (CPV-2) infection is an acute, life-threatening, and highly
contagious viral disease. The infected dogs shed virus in their stool and a variety of diagnostic
methods have been developed for the diagnosis of the infection using fecal samples. Rapid ELISA
tests are commonly used in veterinary practices. However, the accuracy of the results of rapid
tests has been questioned in many reports and a low sensitivity has been reported for these tests.
Methods: The effectiveness of three parvovirus commercial ELISA rapid tests (Zoetis, Abaxis,
and IDEXX) was compared with the laboratory method, qPCR, as a quantitative assay with high
sensitivity and specificity. Using qPCR allows quantitation of the amount of viral target gene in a
sample. Fecal samples from 80 dogs suspected of having CPV-2 infection, based on the clinical
signs, were tested by the three ELISA rapid tests and qPCR method for the presence of canine
parvovirus viral DNA, Specificity, sensitivity, positive, and negative predictive values (PPV and
NPV) for all tests were calculated and compared.
Results: A total of 42 samples qualified for testing based on the inclusion criteria. The results of
qPCR indicated 22 positive samples; however, only 10 of those samples were diagnosed as
positive when ELISA kits were used. There was no difference between the results of the three
ELISA tests from different manufacturers included in the study. The ct-values for the qPCR tests
ranged from 12.03 to 34.21. The ct- values for the samples that were found as false negatives
when ELISA tests were used ranged from 21.12 to 34.21. The sensitivity and specificity of the
ELISA tests were 45.4% and 100% respectively versus 100% sensitivity and specificity for the
gold standard qPCR method. The PPV and NPV values for ELISA tests were 100% and 62.5%,
respectively. Conclusion: ELISA rapid tests are associated with a low sensitivity and therefore,
the negative results should be confirmed using PCR technology to confirm the diagnosis.
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CHAPTER ONE
INTRODUCTION AND GENERAL INFORMATION
Introduction to canine parvovirus
Canine parvovirus (CPV) is the main etiological agent of viral enteritis and the cause of a lifethreatening infection and highly contagious viral disease with mortality of 91% that mainly
affects dogs. This disease is known as one of the most common causes of severe hemorrhagic
diarrhea in puppies and young dogs. It occasionally causes myocarditis in puppies between 6-16
weeks old, however, older animals are sometimes also affected (Kaur G et al., 2014; Nandi S et
al., 2010; Prittie J et al., 2004). Therefore, a quick and safe diagnostic test is crucial to provide
immediate treatment and to prevent viral spread, particularly in high population facilities such as
animal shelters (Nandi S et al, 2010). A variety of ELISA rapid tests are currently in use for
diagnosis of CPV infection in puppies. The ease of the procedure and the low cost of the
operation compared to laboratory methods such as PCR, has made these rapid tests very popular
among veterinarians and animal owners (Esfandiari J et al., 2000). However, low sensitivity and
a high number of false negative ELISA results can lead to underdiagnoses of CPV infection, and
therefore, higher risk for the spread of the disease (Desario C et al., 2005; Schmitz S et al., 2009;
Proksch AL et al., 2015). On the other hand, advantages of PCR techniques, include the
possibility for testing of several samples at the same time with higher sensitivity and specificity.
However, testing animals within 3 to 10 days after vaccination with modified-live vaccine, may
yield false-positive results, even if a PCR technology is used (Faz M et al., 2017). Therefore, in
this study, samples from animals with a history of vaccination within two weeks from sampling
were excluded.

History
Parvovirus CPV2 causes a disease that first emerged among dogs almost three decades ago, in
Europe in the late 1960s. It spread worldwide and caused an epidemic of myocarditis and
gastroenteritis in 1978 killing thousands of dogs and possibly infecting millions more. Canine
parvovirus is closely related to a virus that has been known since the 1920s called feline
panleukopenia virus (FPV) which infect cats and mink and other animals (Parvoviridae,
In Fenner's Veterinary Virology, Fifth Edition, 2017).
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CPV most likely arose as the result of 2 or 3 genetic mutations in FPV that allowed it to increase
its host range to infect dogs (Carmichael LE., 2005).

Canine Parvovirus Taxonomy
Canine Parvovirus is a member of the family of Parvoviridae, divided into two subfamilies:
the Parvovirinae which infect vertebrate hosts, and the Densovirinae, that infect arthropod
hosts. The subfamily Parvovirinae contains five genera Parvovirus, Erythrovirus, Dependovirus,
Amdovirus, and Bocavirus (Cotmore S et al., 2014; Decaro N et al., 2012).
Canine Parvovirus Structure
CPV is a non-enveloped, 26 nm diameter, icosahedral virus, linear, single-stranded negative
sense DNA, and approximately 5 kb in length. This virus contains two major open reading
frames (ORF1 and ORF2) with hairpin structures at both the 5’ and 3’ ends (Parker J, et al.,
2017; Kaur G et al., 2014). The ORF1 encodes nonstructural proteins (NS), and ORF2 encodes
two viral proteins (VP1, VP2) that form the capsid. VP2 plays an important role in determination
of antigenicity of CPV, as a result, mutations of VP2 are responsible for different antigenic
variations (Kaur G et al 2014; Cho Ho-Seong et al., 2006; Phromnoi S et al., 2010). VP1 and
VP2 proteins are translated from substitute splicing of the same mRNA (Reed A et al., 1988).

Virus Variants:
There are two different parvoviruses known to infect dogs. Canine parvovirus type 1 (CPV-1) or
the canine minute virus (MVC), isolated and identified in 1967, which may cause pneumonia,
myocarditis, enteritis, lymphadenitis in puppies aged between 5 and 21 days and neonatal death
(Carmichael LE et al.,1994).
The second variant is the pathogenic canine parvovirus type 2 (CPV-2), an etiologic agent of
canine virus enteritis, was first recognized in 1978. It is one of the important pathogens of
domestic and wild canids causing severe gastroenteritis in young dogs, especially unvaccinated
puppies. CPV-2 attacks the rapidly dividing intestinal crypt epithelium destroys the intestinal
barrier causing hemorrhagic enteritis with severely low white blood cell levels, due to virus
replication in the bone marrow and often results in sepsis (Isola J et al., 2013; Nandi S et al.,
2010). CPV2 is antigenically related to other parvovirus of carnivores similar to feline
panleukopenia virus (FPLV), 98% identical to VP2, differing only in two amino acid in the viral
2

capsid protein. It is also highly similar to raccoon parvovirus (RPV), mink enteritis virus (MEV)
and blue fox parvovirus (BFPV) (Steinel A et al, 2001).
The molecular classification of CPV-2 includes three variants, CPV-2a, CPV-2b and CPV-2c, all
of which can infect young dogs of all different breeds (Parrish CR et al., 1985; Zhao Y et al.,
2013; De la Torre D et al., 2018). CPV-2b and CPV-2c have similar health prospects for dogs,
therefore, it is not necessary to perform sequencing in order to distinguish them from each other
(Malkovich J et al, 2012). However, results of some studies indicate that if CPV-2c infects
vaccinated dogs, it causes more severe disease but this difference may not be detected by
diagnostic tests (Calderon MG et al., 2009).
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CHAPTER TWO
LITERATURE REVIEW
Canine Parvovirus Infection
Canine parvovirus viral infection is highly contagious disease with high mortality and mortality
of 10% (adult dogs) to 91% (unvaccinated puppies) (Nandi S et al., 2010; Appel MJ et al., 1979).
Gastroenteritis is the main clinical sign of the disease combined with lymphopenia and
neutropenia due to damage to the hematopoietic progenitor cells in the bone marrow and
lymphopoietic tissues (Mylonakis M et al,. 2016).

Pathophysiology
Canine parvovirus most likely resulted from genetic mutations in the capsid gene of feline
panleukopenia virus (FPV) and consequently expanded its host range to infect dogs (Ohshima T
et al., 2009). This virus particularly infects and extinguishes rapidly dividing cells such as
lymphopoietic tissue, bone marrow, and the villus epithelium of small-intestinal crypts.
Because high levels of the virus is shed in feces 4-7 days post infection, exposure to infective
feces is the main source of disease transmission. (Kaur G et al., 2014; Nandi S et al., 2010).
Dogs more than 6 months of age and intact males develop CPV enteritis more often than intact
female dogs (Houston DM et al., 1996). However, older dogs are occasionally affected.
Susceptibility rises with a decrease in maternal antibody, intestinal parasitism, or enteric
diseases such as Campylobacter, Salmonella, Giardia, and coronavirus infections. Factors such
as a stressful environment will also increase the risk of severe infection (Mylonakis ME et al.,
2016).
Different breeds have different susceptibility to parvovirus infection; nevertheless, with an
unknown pathophysiology, mixed breeds are known to be less susceptible than pure breeds
(Goddard A et al., 2010). Breeds that have been defined to be at great risk of the disease include
Rottweilers, American Pit Bull, Doberman Pinschers, Terriers, English Springer Spaniels, and
German Shepherds (De Cramer K et al., 2011).

Clinical Signs
The major clinical symptoms of canine parvovirus are generally associated with the intestinal
form of the canine parvovirus with severe bloody diarrhea, lethargy, weakness, loss of appetite,
4

malaise, vomiting, high fever (or hypothermia), and dehydration. It is worth noting that the
absence of bloody diarrhea does not necessarily rule out CPV infection (Folitse R et al., 2018;
Kelly D. Mitchel Merck manual, canine parvovirus). The disease is categorized by two
noticeable clinical forms (i) enteritis in adult dogs and (ii) myocarditis in puppies. The virus can
distress myocardial cells, which leads to acute heart failure and unexpected death in
young puppies (Nandi S et al., 2010; Kilian E et al., 2018). Diarrhea may be seen in dogs of any
age but appears frequently in puppies of less than 3 months of age (Nandi S et al., 2010). In
severe cases, stool may be watery, or yellowish with blood. Dogs with enteritis show extreme
pain and their appetite may be affected, resulting in rapid weight loss (Mylonakis M E et al.,
2016). Damage of the intestinal crypt epithelium results in epithelial necrosis, impaired
absorptive capacity, villous atrophy, and interruption in gut barrier function which can result in
bacterial translocation and bacteremia (Nandi S et al., 2010). In the early stage of the disease, a
minor increase in temperature is observed but it will slowly turn to subnormal temperatures.
(Nandi S et al., 2010).

Transmission
Canine parvovirus can spread in three ways: Fecal– oral route, Oro-nasal contact, and
contaminated fomites of canine, cats, raccoons, mink, coyotes, wolves, and other wild animals.
Moreover, a frequent cross-species transmission has been reported (Allison AB et al., 2013).
Infected dogs shed the virus in their stool in large amounts after exposure (Kaur G et al., 2014;
Nandi S et al., 2010; Miranda C et al., 2016), and since CPV is very stable in the environment, it
can survive more than a year in feces and soil over extremes of heat, cold, or humidity.
Therefore, contaminated environments can remain a source of infection for months. As a nonenveloped virus, CPV is also very resistant to disinfectants (Nandi S et al., 2010).

Diagnosis of Parvoviral infection
Since this disease is extremely contagious, a fast and reliable diagnostic test is necessary to
detect virus-shedding animals and to provide the necessary intensive care for diseased animals
(Proksch AL et al., 2015). Another challenge in diagnosis of CPV infection is that several other
pathogens such as rotavirus or campylobacter infections may result in the same clinical
symptoms of parvovirus, therefore, diagnosis based on the clinical signs may be misleading
(Ortega AF et al., 2017).
5

Several methods have been developed to confirm CPV infection. Currently, six different
laboratory tests for diagnosis of canine parvovirus type 2 (CPV-2) are available including
immunochromatography, virus isolation, haemagglutination, enzyme-linked immunosorbent
assay (ELISA), and polymerase chain reaction (PCR) (Desario C at al., 2005).
Among these techniques, ELISA testing of the fecal samples to detect the CPV-2 antigen is
considered a simple, quick, and reliable method by some reports (Kumar M et al, 2010).
However, other conflicting reports indicate that ELISA testing is associated with a high
percentage of false-negative results due to low viral shedding in earlier or later stages of the
infection. In addition, this technique has reported to be associated with poor sensitivity compared
to PCR (Proksch AL et al., 2015). False positive ELISA results may be due to several reasons
particularly recent vaccination with modified live vaccines. Therefore, it is recommended that
every positive ELISA test should be verified by PCR, or additional supportive diagnostics
(Mylonakis ME et al., 2016).
PCR technology is known as a reliable method for diagnosis of this disease. Conventional or
traditional PCR (cPCR) and quantitative PCR (qPCR) are the two main methods used for
diagnostic purposes. c-PCR compares the intensity of the amplification of a specific DNA
sequence on a gel to a size standard, called a ladder, to identify the approximate size of the DNA.
cPCR is the most basic type of PCR reaction. It is a semi-quantitative method that provides
qualitative results and a post-PCR step involved for detection or visualization of the DNA.
In this method, the results are not expressed as numbers and interpretation of the results is often
limited to either positive or negative. In addition, cPCR is a time consuming method (3-6 hours
versus 30 min to an hour for qPCR). The resolution in cPCR is poor and therefore the sensitivity
of the test is low. In contrast, in qPCR, as a quantitative method, the amplified DNA is
commonly detected with probes that contain fluorescent dyes and the amount of the fluorescence
released during amplification has direct association with the amount of the amplified DNA.
qPCR collects the data in the exponential growth phase with high resolutions and results are
expressed numerically ( Staggemeier R et al., 2015; Geng Y et al., 2017; Espy M J et al., 2006).
Therefore, the qPCR method is mostly used for quantitation of gene expression and viral
quantitation, while the cPCR method is useful for sequencing, genotyping and cloning (Nandi S
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et al., 2010; Desario C et al., 2005; Decaro N et al., 2005). In addition, with the ability to
determine the cut-off points, q-PCR allows for differentiation between carrier animals versus
those with active disease. Therefore, the qPCR technique is known as the sensitive, and optimal
detection method for parvoviral infection and is considered a standard tool for both diagnostics
and research purposes (Mackay et al, 2002).

Treatment of Canine Parvoviral Infection
Treatment of canine parvovirus has to be aggressive. It involves the use of broad-spectrum
antibiotics, injectable anti-emetics and intravenous fluid therapy. Death may be the result of
dehydration or secondary infection rather than the virus itself. Furthermore, myocarditis may
increase the severity of the disease as it spreads quickly in the domestic dogs compared with the
wild populations (Nandi S et al., 2010). Systemic antibiotics such as ampicillin and cefoxitin are
used as single treatments or in combination with enrofloxacin to prevent septicemia (Mylonakis
M E et al., 2016). Intravenous fluid therapy is used to prevent dehydration from fluid loss
through vomiting and diarrhea. A study has demonstrated the benefits of probiotic treatment in
hemorrhagic diarrhea. (Arslan H et al., 2012; Ziese AL et al., 2018; Jensen AP et al., 2019)

Vaccination against Canine Parvoviral Infection:
The morbidity and mortality rate in unvaccinated puppies can reach up to 91% (Nandi S et al.,
2010; Parker J et al., 2017). However, currently, inactivated and modified live vaccines used to
protect against canine parvovirus have significantly reduced the prevalence of the disease.
Nevertheless, outbreaks still occur frequently which presumably arise in unvaccinated or undervaccinated puppies (Nova BW et al., 2018). Studies indicate that the majority of the animals at
the age of 12 weeks respond to vaccines; however, colostrum may affect the response of the
animal to vaccination. Other reasons for vaccine failure may include introduction of new
antigenic variants and existence of maternal antibodies (Nandi S et al., 2010; Meeusen E et al.,
2007).
Considering that canine parvovirus infection is a very contagious disease, a quick and safe
diagnostic test is crucial to provide immediate treatment and to prevent viral spread. Therefore it
is important to evaluate the effectiveness of the diagnostic methods for this disease, particularly
those that are commonly used in clinical practice, the rapid ELISA snap tests.
7

CHAPTER THREE
MATERIALS AND METHODS
Sample Collection
A total of 80 stool samples were collected from various breeds of dogs exhibiting clinical signs
of canine parvovirus infection (fever, anorexia, bloody stool, diarrhea, vomiting, and/or
depression) over the course of two years (2018-2020). Dogs included in this study originated as
referral patients to University of Tennessee Veterinary teaching hospital or from several
veterinary clinics and animal shelters in East Tennessee. The inclusion and exclusion criteria for
evaluating the samples are listed in Table 1. Based on these criteria, 38 samples were excluded
due to canine parvovirus (CPV) vaccination within 2 weeks of sample collection. Forty-two dogs
with symptoms of CPV infection that were also at least two weeks post-vaccination from the
date of sample collection, were included in the study. All stool samples were stored at -20°C
until analysis.

Sample Analysis
Analysis of the stool samples required several preparatory steps as described below:
A) Sample screening using q-PCR
To perform a diagnostic q-PCR, the following steps were followed:
1) Primers and Probe Design. One pair of primers, forward and reverse, were designed
using the Primer3 software package (Integrated DNA Technologies, Inc. San Diego, CA USA).
These primer sequences, obtained using BLAST searches against CPV, target a 144 bp region of
the non-structural (NS) gene that encodes a nuclear protein that is crucial for viral replication
(Table 2).
2) DNA Isolation. DNA was extracted from the 42 fecal samples included in this study
according to the manufacturer’s instructions (QIAGEN, QIAamp DNA Micro Kit, Thermofisher
Scientific Waltham, MA USA). DNA extracts from the feces of a healthy dog were used as a
negative control. The PCR reactions included 20 µL master-mix (Ex-Taq HS master mix; Takara
Bio Inc.), 1.5 µL of each primer, 1uL probe labeled with FAM dye with Black Hole Quencher,
and 5 µL of extracted DNA. The reactions were carried out using Cepheid Smart Cyclers
8

(Cepheid Smart Cycler ®, Sunnyvale CA, USA) under the following reaction parameters: Initial
denaturation at 95°C for 120 seconds followed by 45 cycles of 95°C for 15 seconds, annealing
at 60°C for 30 seconds, and extension at 72°C for 30 seconds.
B) ELISA Screening
All 42 samples were additionally evaluated using each of three commonly-used commercial
ELISA kits for detecting canine parvovirus, including SNAP Parvo Test from IDEXX (IDEXX
Laboratories, Inc. Westbrook, Maine USA),VetScan Canine Parvovirus Rapid Test form Abaxis
(Abaxis, Inc. Company Union City CA USA) and WITNESS® Parvo Rapid Test from Zoetis
(Zoetis Company Kalamazoo MI USA) following the manufactures instructions.
C) DNA/Ct-Value Standard Curve Preparation
In order to calculate the sensitivity and specificity of the ELISA tests compared to real time
PCR, virus was cultured on CRFK (Crandall Reese Feline Kidney) cells and titered to generate a
standard curve of DNA concentration versus Cycle threshold (Ct-value, the value at which
fluorescence detection surpassing a threshold fluorescence value of 30 fluorescence units
indicates template amplification).
1) Cell Culture. In order to prepare a cell culture to be infected with parvovirus, CRFK
cells were cultured on Dulbecco's Modified Eagle Medium (DMEM) (Thermofisher scientificGibco Pittsburgh PA USA) with 10 mL of pen/strep (100 Mg/ml Penicillin and 100 U/ml
Streptomycin) and 50 mL of fetal bovine serum (FBS) (Thermofisher scientific-Gibco Pittsburgh,
USA) in sterile 25 cm2 culture flasks at 37°C under 5% CO2. Cell cultures were frequently
examined for confluency. Once 100% confluency was achieved (5-7 days from incubation), cells
were re-suspended using 0.25% trypsin containing 2.21 mM EDTA (CorningTM, Rochester, NY
USA). Finally, cells were suspended in freezing medium (10% DMSO in DMEM/F12) (Spectrum
chemical & laboratory products, Gardena, CA USA) and subjected to sequential cooling at 4°C, 20°C, and -80°C.
2) Virus Propagation and Isolation. For virus propagation, the preserved CRFK cells
from the previous stage were thawed and transferred to 5 sterile cell culture flasks and incubated
at 37°C. At 50% confluency, cells were inoculated with 200 μl of CPV dispensed through a
0.2 μm sterile membrane filter (Whatman Puradisc syringe filtersTM GE Healthcare & Cytiva
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,Cleves, OH USA). Cultures were observed daily for five days to monitor the cytopathic effect
(CPE), indicated by cell rounding and/or total lysis of the monolayer (Figure 1). Infected
Cultures were then trypsinized and the virus was harvested on day 5 post-inoculation. Briefly,
the cells were lysed using three sequential freeze-thaw cycles to release the intracellular virus.
The suspension was then centrifuged at 6000 rpm for 15 minutes at 4°C, and qPCR was
performed on extracts of the supernatant to confirm the presence of the virus. Following
confirmation of virus (via low Ct on qPCR), one mL aliquots of supernatant were collected and
stored at -80°C as virus stocks.
3) Construction of Positive Control Plasmid. DNA was extracted from aliquots of virus
stock following the manufacturer’s protocol (QIAGEN, DNA Mini Kit), and the gene encoding
the major non-structural protein of the virus, NS1, was amplified by PCR as described above.
The qPCR products(ranges from base 492 to base 636 of the CPV genome) were sub-cloned into
the TOPO-TA vector (TOPO® cloning Kit, Invitrogen USA, Inc.), a vector with covalentlylinked topoisomerase that relies on A-T complementarity for integration. This construct was then
used to transform One Shot® Chemically Competent Escherichia coli following the
manufacturer’s protocol. Putative transformants were plated on Luria-Bertani (LB) plates
containing ampicillin and enzyme substrate for Lac-Z blue/white screening (imMedia TM Amp
Blue for lacZ+ Amp, Invitrogen USA) and incubated overnight at 37°C. After 24 hours,
colonies were screened and transferred to LB Broth and shaken overnight at 37°C. Plasmids
were isolated using the Gene JET plasmid mini-prep kit (Thermofisher Scientific Company
Baltics, UAB, Vilnius Ethuania) following the manufacturer’s protocol. The isolated plasmids
were sequenced using M13 and T7 vector sequences flanking the putative NS1 sequence insert.
4) Standard Curve Generation. Following sequence confirmation, a 10-fold serial
dilution of the isolated plasmid was prepared to a 10-8 final dilution. Three replicates of each
dilution were analyzed using qPCR as described above. The Ct-value from each triplicate was
averaged and reported as the final Ct-Value for that dilution. The qPCR efficiency was calculated
using efficiency, percent efficiency, and PCR efficiency equations
Standard curve line equation
y = mx + b
10

Where:
y = Ct value
m = slope
x = log (quantity)
b = intercept
Efficiency (%) = 10^ (-1/Slope) x 100

Data Analysis:
The association between binary outcomes of qRCR and ELISA tests was evaluated using a Chisquare test. Sensitivity, specificity, positive predictive values, and negative predictive values
were calculated using the frequency tables. A receiver operating characteristic curve (ROC) was
generated to illustrate the diagnostic ability of methods other than qPCR. A post hoc power
analysis was conducted to confirm that the current sample size was large enough to detect the
difference between the two methods with a power of at least 80%. Statistical significance was
identified with a baseline p-value of 0.05. Analyses were conducted in SAS 9.4 TS1M6 for
Windows 64x (SAS institute Inc., Cary, NC, USA).
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CHAPTER FOUR
RESULTS AND DISCUSSION
In this study, a total of 80 fecal samples were collected. Of those, 42 samples (~52%) with a
known history of vaccination at least two weeks before sample collection were analyzed. Based
on the post hoc power analysis, a minimum of 13 samples would be needed to detect the
difference between qPCR and ELISA methods with a power of at least 80%, therefore, the 42
samples analyzed in this study were well above the minimum number necessary. Animal
demographics and predominant clinical symptoms for the included animals are provided in Table
4 and Figure 2.
The results of qPCR and ELISA testing are presented in tables 5 and 6. Based on these results,
there was significant difference between the results obtained by qPCR and all ELISA kits
(p=0.0006). However, ELISA methods from the three manufacturers performed similarly and
their results were identical. The generated ROC curves for ELISA tests resulted in an area under
the curve (AUC) of ~ 73% (>50%), indicating that these methods have high specificity (i.e., the
capability of identifying negative cases) but lower sensitivity (i.e., the capability of identifying
positive cases) (Figure 4).
A total of 22 positive samples were detected using qPCR, but ELISA testing failed to detect 12
positive samples (54%), out of the 22 detected by qPCR. The PCR products of 12 samples with
high ct-values were sequenced and the nucleotide sequence of the CPV gene was determined in
all samples. Sensitivity, specificity, positive predictive value (PPV) and negative predictive
values for each technique are listed in Table 7.
Based on these results, ELISA rapid testing is associated with a high specificity but lacks an
ideal sensitivity. Poor sensitivity of ELISA rapid testing is also reported in other studies when
compared to the PCR assay (Desario C et al., 2005; Faz M et al., 2017).
The range of Ct-Value for the 22 positive samples using qPCR, was 12.03 to 34.21. In Figure 3,
the positive samples detected by qPCR are shown in association with the prepared Ct-Value
/DNA standard curve.
The Ct-Values for the positive samples that were reported as false negatives in ELISA tests
ranged from 21.12 to 34.21 indicate the established real-time has reliably in detecting the low
12

amounts of CPV-2 in clinical samples. The higher Ct-Value indicate the lower concentration of
the viral antigen, therefore the results of this study clearly indicate that ELISA rapid tests fail in
detecting the lower load of the viral antigen and result in false negative results. Based on the
results of this study, the Ct-Value of 21.12 is, considered the cutoff point for the ELISA rapid
tests to be accurate (Figure 5). In terms of the clinical interpretation of these results, if a positive
ELISA test result is obtained, the diagnosis of CPV enteritis is projected to be correct. However,
a negative ELISA test may indicate a false negative result due to a lower fecal load of CPV
antigen resulting from milder disease, or watery diarrhea. Other causes of false negative results
may include mutation of the CPV strain, technical issues in performing the test or sampling
errors (Faz M et al., 2017; Proksch AL., 2015).
In relation to the PCR technologies, though the sensitivity and specificity is ideal, if a mutated
CPV strain is causing the disease, even the PCR method may fail in detecting true positive
samples (Proksch AL., 2015). The use of nucleic acid–based testing is recommended to ensure
that mutations have not occurred (Hong C et al., 2007).
Therefore, if the PCR results of CPV testing is negative but clinical signs and hematological and
biochemical parameters are strongly suggesting a parvoviral infection, it is imperative to
consider other testing methods such as nucleic acid-base testing to determine a potentially
mutant strain or isolate the virus to be able to derive a definite diagnosis of parvoviral disease.
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CHAPTER FIVE
CONCLUSIONS
Conclusion
ELISA rapid (snap) testing is a suitable testing method only for screening, as particularly in
lower load of the viral antigen, the sensitivity of these tests is very low which may lead to
misdiagnosis and further increase in mortality and spread of the infection. In contrast, PCR
technology has a high sensitivity and specificity, and therefore, the negative ELISA test results
should be confirmed by PCR to improve the accuracy of the diagnosis.
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Table 1: Inclusion and Exclusion Criteria for Samples
Criteria
Patient’s history
•

Vaccination for CPV within 2 weeks before sampling

Inclusion

•

Diarrhea

Criteria

•

Lethargy

•

Loss of appetite

•

Bloody diarrhea

•

Depression

•

Anorexia

•

High body temperature (over 103 degrees)

•

Vomiting

•

Dogs with known history of at least 2 weeks post-vaccination from

Exclusion
Criteria

sample collection date
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Table 2: Primers and Probes
Primer/ Probe
Sequence (5’-3’)
CPV-Forward

5’-GAC TGG GAA TCG GAA GTT GA 3’

CPV-Reverse

5’-GAA TGC CAG CCT TGA TCT TT 3’

Probe

5’-56-FAM/TCG CCA AAA/ ZEN/AGC AAG TAC AA/31ABKFQ/-3’

22

Table 3: DNA Concentration and Associated Ct values for DNA Dilutions Used to Prepare the
Standard Curve.
Dilutions

DNA copies/mL

Log DNA copies/mL

Ct- values

10-8

10

1

31.78

10-7

100

2

29.93

10-6

1000

3

27.04

10-5

10000

4

24.07

10-4

100000

5

21.21

10-3

1000000

6

16.83

10-2

10000000

7

15.15

10-1

100000000

8

12.22
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Table 4: Demographics of 42 Animals that were Included in the Study:
Sex
Number
Age
Female

19(45%)

7 Weeks- Adult

Male

23(55%)

6 Weeks-Adult
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Table 5: Parvovirus Testing Results of 42 Canine Fecal Samples Using qPCR and ELISA.
ELISAs
q-PCR
IDEXX
Abaxis
Zoetis
Positive

22

10

10

10

Negative

20

32

32

32

Total

42

42

42

42
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Table 6: Results of Three Different Brands of ELISA tests and q-PCR with Ct Values
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Table 6: Continued.
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Table 7: Comparing Sensitivity, Specificity, PPV, and NPV for PCR and ELISA tests performed
on 42 fecal samples suspected of parvoviral infection.
Testing Method
Sensitivity
Specificity
PPV
NPV
q-PCR

100

100

100

100

ELISA

45.4

100

100

62.5
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A
B
Figure 1. Uninfected (A) and infected (B) CRFK cells under an Inverted Microscope.
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Figure 2: Predominant clinical signs in the 42 animals included in the study.
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Standard Curve-qPCR
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Figure 3: DNA concentration/Ct values standard curve. The qPCR had a linear dynamic range
between 10 8 and 101copies, with a slope of −2.908, a y-intercept of 35.36, and a mean
coefficient linearity (R2) of 0.9937.
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ROC Curve for Model
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Figure 4: ROC curve to illustrate the diagnostic ability of the ELISA rapid
tests used in this study.
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Figure 5: q-PCR positive samples plotted on the Ct/DNA concentration standard curve.

33

9

VITA
Niloofar Khajeh-Kazerooni was born on December 8, 1969 and grew up in one of the
oldest and most populous cities of Iran: Shiraz. Shiraz is known as the ancient city of poets,
literature, wine, and flowers. She attended high school in the same city and graduated in 1987.
She was then accepted to Azad University where she majored in Microbiology with a minor in
Biological Science in 1989, receiving her Bachelor of Science in May of 1993.
During her undergraduate studies, she participated in numerous trainings and workshops
at Shiraz University Hospital. After receiving her bachelor’s degree, she worked in a diagnostic
lab as a technician. In 2003, she immigrated to the United States from Iran, but, due to the
regulations of her visa, she was not able to continue her studies. Instead, she volunteered in
various locations including libraries and diagnostic labs. Finally, after 10 years, in 2013, she
received her Green Card and was able to work in the United States. She was hired at the
University of Tennessee College school of Veterinary Medicine (UTCVM), where she
previously held a position as a laboratory technician and research aide. She began her work
under the title of Laboratory Technologist II and advanced to Research Technician I and finally
to her current title of Senior Laboratory Technologist II.
Four years into her career at UTCVM, she was accepted into the Comparative and
Experimental Medicine program at the college and began her studies as a master’s student.
Niloofar’s research has focused on the diagnostics of canine parvovirus and the evaluation of the
ELISA snap test. The work in her thesis further investigates the specificity and sensitivity of the
ELISA test, which is used routinely in diagnostic labs, veterinary clinics and animal shelters.

34

